May. 27 at 10:40 AM
JPMorgan🏁
$LRMR and said: We are initiating coverage of Larimar Therapeutics (LRMR) with an Overweight rating and a Dec 2027 price target of
$9.
$PTCT SLDB BIIB DSGN
$LXEO
Larimar's lead asset is nomlabofusp (nomla; CTI-1601), a subcutaneously administered, recombinant fusion protein designed to deliver frataxin (FXN) to the mitochondria of patients with Friedreich's ataxia (FA), a rare neurodegenerative disorder.
In the near-term, in 2Q26, we expect to see topline results from the ongoing open-label (OL) study as well as feedback from the company's type B meeting with the FDA to align on the overall BLA package readiness.
The company expects a rolling BLA submission for accelerated approval (AA) in June 2026, pending FDA feedback, using skin FXN levels as a surrogate endpoint, with the final submission including the CMC module expected in 2H26; if approved, nomla would be the first FXN replacement therapy for FA, with a potential U.S. approval and launch in 1H27.
